Lowest Price Guaranteed From USD 2,199
Published
January 2016
Pages
218
View Count
8122
Example Insights
An updated edition is available at the following link
Report Description
The term “microbiota” refers to specific clusters of commensal, symbiotic and pathogenic microorganisms that reside in various regions on and within the human body. The human microbiome is involved in various functions that are essential to lead a healthy life. Majority of the microorganisms benefit humans by supplementing them with traits that they would otherwise not possess. These include metabolism of complex carbohydrates, renewal of gut epithelial cells and prevention of growth of pathogens. However, several microorganisms are associated with pathogenic organisms or have the capability of translating into a disease-causing microbe.In fact, an imbalance in the human flora or dysbiosis is also seen to be associated with several long-term diseases. During dysbiosis, it is observed that with the reducing number of beneficial microbes, there is a concurrent increase in the number of harmful microbes. The increase in the number of pathogenic microbes further leads to the development of several harmful diseases such as inflammatory bowel disease (IBD), cancer, bacterial vaginosis (BV), obesity and chronic fatigue syndrome.
In addition to the existing treatment plans for such health conditions, approaches that modify natural formulations by adding or removing individual microbes or entire microbial communities have been shown to have a significant impact on the health of an individual. Usingmicrobiome as a therapy has unique advantages over traditional small molecules or biologics.It can be used to identify individual therapeutic microorganisms and help in designing the therapies customised to the patient’s microbiome. Unlike the adverse effects posed by the prolonged use of drugs such as the antibiotics, microbiome therapeutics have a lower risk of toxicity associated with them. In addition, microbiome based therapies provide a rich source of new biomarkers helping in the classification of the patients into relatively homogeneous subpopulations.
Currently, there are many popular probiotics, prebiotics, medical food and supplements commercially available in the market as OTC products. These products are known to prevent a number of diseases by restoring the human microbiome to its natural state. However, these products cannot be used as a replacement for medication or as a treatment for the eradication of the disease. The overall microbiome therapeutics market is still in its infancy with no approved drugs; Faecal microbial transplant (FMT) is the only microbiome related therapy that has entered the market. With several firms and investors displaying a growing interest in this field, the overall market holds a strong potential in the coming years.
Scope of the Report
The ‘Microbiome Therapeutics Market, 2015-2030’ report provides a comprehensive study on the current landscape and the future outlook of the evolving pipeline of products in this area. Imbalance in the natural microbiota are a known cause for many chronic diseases such as antibiotic associated diarrhoea (AAD), Clostridium difficileinfections (CDI), irritable bowel syndrome (IBS), diabetes, Crohn’s disease and ulcerative colitis. While the field has gathered the interest of several companies, there are no approved microbiome drugs available in the market yet; FMT is the only commercially available therapy. The development pipeline of microbiome therapeutics, though, has several promising candidates that are likely to result in commercial success stories in the foreseen future.
Among other elements, the report also elaborates on new microbiome based diagnostic solutions being developed and the upcoming opportunities in this market for different stakeholders. As pharmaceutical companies continue to initiate and expand their research programs in this area, one of the key objectives outlined for this report was to understand the future potential of the market. This was done by analysing:
The study provides a detailed market forecast and opportunity analysis for the short-mid term (2015-2022) and long term (2022-2030). The research, analysis and insights presented in this report include potential sales of FMT therapies and drugs in late stages of development. Our opinions and insights, presented in this study, were influenced by several discussions we conducted with experts in this area. These included senior representatives at Assembly Biosciences, Da Volterra, Metabiomics, MicroBiome Therapeutics and Rebiotix. All actual figures have been sourced and analysed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
Contents
Chapter 2 provides an executive summary of the report. It offers a high level view on where the microbiome therapeutics market is headed in the mid to long term.
Chapter 3 provides a general introduction to the underlying concepts on the human microbiota. In addition to reviewing the function of microbiota, we have also discussed key aspects of the human microbiome project and the diseases caused by imbalance in the microbiota. Further, we have highlighted the need for microbiome therapeutics along with a brief description of the existing FMT therapies.
Chapter 4 includes information on over 100 molecules that are currently in different stages of development (both clinical and preclinical/discovery). In this section, we have presented a detailed analysis of the microbiome therapeutics development pipeline including information on the phase of development, indications and the type of products. In addition, the chapter contains details on different microbiome based diagnostics, medical foods and over-the-counter (OTC) supplements that are approved or under development.
Chapter 5 provides information on the various types of probiotic and prebiotic drugs that are being developed as microbiome therapeutics. It features a detailed discussion on their mode of action, range of formulations and the different disease areas likely to benefit from the use of these drugs.
Chapter 6 highlights the promising therapeutic areas for microbiome therapeutics. These indications are the prime focus of companies developing microbiome based drugs. The chapter also highlights the epidemiological facts and currently available treatment options for each indication.These therapeutic areas include gastrointestinal (GI) disorders, inflammatory disorders, metabolic disorders and women disorders.
Chapter 7 presents details on various investments and grants received by companies focused in the area of microbiome therapeutics. The analysis highlights the growing interest of the VC community and other strategic investors in this market.
Chapter 8 features an elaborate discussion on the collaborations and partnerships that have been forged amongst players in this market. We have also discussed the various partnership models in existence and the most common forms of deals/agreements that have evolved over time.
Chapter 9 highlights the monetary opportunity presented by these therapies.The analysis highlights the likely evolution of important parameters such as the target patient population and the likely market penetration rates. We have also presented an indicative distribution of the overall market across the well-known therapeutic areas.
Chapter 10 provides detailed company and drug profiles of the leading players in the market. Each profile includes information such as the company’s financial performance (wherever available), geographical presence, pipeline of microbiome therapeutics and recent collaborations.
Chapter 11 summarises the overall report. In this chapter, we provide a recap of the key takeaways and our independent opinion based on the research and analysis described in previous chapters.
Chapter 12 is a collection of interview transcripts of the discussions that were held with key stakeholders in this market. These include JP Benya (Vice President, Business Development of Assembly Biosciences),Pierre-Alain Bandinelli (Chief Business Officer of Da Volterra), Gregory J. Kuehn (Vice President, Business Development and Marketing of Metabiomics), Dr. Mark Heiman (Vice President of Research and Chief Scientific Officer of MicroBiome Therapeutics) and Lee Jones (President and CEO of Rebiotix).
Chapter 13 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.
Chapter14 is an appendix, which provides the list of companies and organisations mentioned in the report.
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Defining Microbiota and Microbiome
3.2. Discovery of the Human Microbiome
3.3. The Human Microbiome Project (HMP)
3.3.1. Project Approach
3.3.2. Project Initiatives
3.3.3. Project Achievements
3.4. Functions of the Human Microbiome
3.5. The Gut Flora
3.5.1. Role of Gut Microbiota
3.5.2. Imbalance in the Gut Flora
3.6. Development of Microbiota in Infants
3.6.1. Mode of Delivery
3.6.2. Type of Feeding
3.6.3. Use of Antibiotics by the Mother
3.7. Relationship between the Human Microbiome and Diseases
3.7.1. Cancer
3.7.2. Inflammatory Bowel Disease (IBD)
3.7.3. Obesity
3.7.4. Type-2 Diabetes
3.8. Need for Microbiome Therapies
3.9. Faecal Bacteriotherapy: A Powerful Tool to Restore Healthy Gut Microflora
3.9.1. FMT and FDA Regulation
4. MICROBIOME THERAPEUTICS AND DIAGNOSTICS: MARKET LANDSCAPE
4.1. Chapter Overview
4.1.1. Development Pipeline of Microbiome Therapeutics
4.1.1.1. Distribution by Phase of Development
4.1.1.2. Distribution by Type of Product
4.1.1.3. Distribution by Geography
4.1.1.4. Distribution by Therapeutic Area
4.1.1.5. Active Industry Players
4.1.2. Development Pipeline of Faecal Microbiota Transplant
4.1.3. Development Pipeline of Diagnostic Applications
4.1.4. Development Pipeline of Medical Food, Supplements and Consumer Products
5. PROBIOTIC AND PREBIOTIC DRUGS
5.1. Chapter Overview
5.2. Probiotic Drugs
5.2.1. Introduction
5.2.2. Types of Probiotics
5.2.3. Therapeutic Areas Benefiting from Probiotics
5.2.3.1. Antibiotic-Associated Diarrhoea (AAD)
5.2.3.2. Infectious Childhood Diarrhoea
5.2.3.3. Cholesterol
5.2.3.4. Inflammatory Bowel Disease (IBD)
5.2.3.5. Blood Pressure
5.2.3.6. Lactose Intolerance
5.2.3.7. Weight Loss
5.2.3.8. Vitamin Production
5.2.3.9. Bacterial Vaginosis (BV)
5.2.4. Side Effects of Probiotics
5.3. Prebiotic Drugs
5.3.1. Introduction
5.3.2. Source of Prebiotics
5.3.3. Types of Prebiotics
5.3.3.1. Fructo-Oligosaccharides
5.3.3.2. Galacto-Oligosaccharides
5.3.3.3. Inulin
5.3.4. Therapeutic Areas Benefiting from Prebiotics
5.3.4.1. Antibiotic Associated Diarrhoea (AAD)
5.3.4.2. Constipation
5.3.4.3. Gastrointestinal (GI) Disorders
5.3.5. Dysbiosis
5.4. Development Pipeline of Probiotic/Prebiotic Drugs
5.4.1. Distribution by Phase of Development
5.4.2. Distribution by Therapeutic Area
5.4.3. Distribution by Geography
5.4.4. Distribution by Company
6. KEY THERAPEUTIC AREAS
6.1. Chapter Overview
6.2. Gastrointestinal (GI) Disorders
6.2.1. Clostridium difficile Infections (CDI)
6.2.1.1. Disease Description
6.2.1.2. Epidemiology
6.2.1.3. Current Treatment Plans
6.2.1.4. Microbiome Therapies for CDIs and Other Hospital Acquired Diseases
6.2.2. Irritable Bowel Syndrome (IBS)
6.2.2.1. Disease Description
6.2.2.2. Epidemiology
6.2.2.3. Current Treatment Plans
6.2.2.4. Microbiome Therapies for IBS
6.3. Inflammatory Disorders
6.3.1. Ulcerative Colitis
6.3.1.1. Disease Description
6.3.1.2. Epidemiology
6.3.1.3. Current Treatment Plans
6.3.1.4. Microbiome Therapies for Ulcerative Colitis
6.3.2. Crohn's Disease
6.3.2.1. Disease Description
6.3.2.2. Epidemiology
6.3.2.3. Current Treatment Plans
6.3.2.4. Microbiome Therapies for Crohn's Disease
6.4. Metabolic Disorders
6.4.1. Diabetes
6.4.1.1. Disease Description
6.4.1.2. Epidemiology
6.4.1.3. Current Treatment Plans
6.4.1.4. Microbiome Therapies for Diabetes
6.4.2. Obesity
6.4.2.1. Disease Description
6.4.2.2. Epidemiology
6.4.2.3. Current Treatment Plans
6.4.2.4. Microbiome Therapies for Obesity
6.5. Women Disorders
6.5.1. Bacterial Vaginosis (BV)
6.5.1.1. Disease Description
6.5.1.2. Epidemiology
6.5.1.3. Current Treatment Plans
6.5.1.4. Microbiome Therapies for BV
7. VENTURE CAPITAL INTEREST
7.1. Chapter Overview
7.2. Instances of Funding for Development of Microbiome Therapeutics and Diagnostics
7.3. Rising Venture Capital Interest
7.4. Funding Instances: Distribution by Type of Funding
7.5. Leading Players: Distribution by Number of Funding Instances
7.6. Most Active VC Firms/Institutions
7.7. Most of the Funding is Targeted Towards Therapeutic Applications
8. RECENT COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models/Agreements
8.3. Microbiome Therapies: Recent Collaborations
8.4. Distribution by Month/Year
8.5. Distribution by Type of Application
8.5.1. Distribution by Type of Therapeutic Product
8.6. Distribution by Type of Partnership
8.7. Most Active Companies with Multiple Collaborations
9. MARKET SIZING AND OPPORTUNITY ANALYSIS
9.1. Chapter Overview
9.2. Forecast Methodology
9.3. Microbiome Therapeutics Market: Key Assumptions
9.4. Microbiome Therapeutics Market: Opportunity Analysis
9.4.1. Overall Microbiome Therapeutics Market, 2015-2030
9.4.2. Microbiome Therapeutics Market, 2015-2030: Distribution by Therapeutic Area
9.4.3. Microbiome Therapeutics Market, 2015-2030: Distribution by Application
10. COMPANY PROFILES
10.1. Chapter Overview
10.2. C3 Jian
10.2.1. Company Overview
10.2.2. Product Portfolio
10.2.2.1. Therapeutics
10.2.2.2. Diagnostics
10.3. Enterome Bioscience
10.3.1. Company Overview
10.3.2. Product Portfolio
10.3.2.1. Therapeutics
10.3.2.2. Diagnostics
10.3.3. Collaborations
10.4. Immuron
10.4.1. Company Overview
10.4.2. Financial Performance
10.4.3. Product Portfolio
10.4.4. Collaborations
10.5. MicroBiome Therapeutics
10.5.1. Company Overview
10.5.2. Product Portfolio
10.6. OpenBiome
10.6.1. Company Overview
10.6.2. Financial Performance
10.6.3. Product Portfolio
10.7. Osel
10.7.1. Company Overview
10.7.2. Product Portfolio
10.7.3. Collaborations
10.8. Rebiotix
10.8.1. Company Overview
10.8.2. Product Portfolio
10.8.3. Collaborations
10.9. Ritter Pharmaceuticals
10.9.1. Company Overview
10.9.2. Financial Performance
10.9.3. Product Portfolio
10.9.4. Collaborations
10.10. Second Genome
10.10.1. Company Overview
10.10.2. Second Genome Solutions
10.10.3. Product Portfolio
10.10.4. Collaborations
10.11. Seres Therapeutics
10.11.1. Company Overview
10.11.2. Financial Performance
10.11.3. Product Portfolio
10.11.4. Collaborations
10.12. Synthetic Biologics
10.12.1. Company Overview
10.12.2. Financial Performance
10.12.3. Product Portfolio
10.12.4. Collaborations/Recent Developments
11. CONCLUSION
11.1. Imbalance in the Human Microbiota Leading to Rising Chronic Disorders
11.2. Increasing Antibiotic Use is The Primary Cause of Microflora Disturbance
11.3. Microbiome Therapy Offers a Potential Solution to Preserve the Human Microflora
11.4. Several Initiatives are Still in Early Stages of Development
11.5. An Active Support from Regulatory Authorities Likely to Drive High Accessibility
11.6. With a Strong Preclinical Backup, We Expect Steady Growth in the Coming Years
12. INTERVIEW TRANSCRIPTS
12.1. Chapter Overview
12.2. JP Benya, Vice President, Business Development, Assembly Biosciences
12.3. Pierre-Alain Bandinelli, Chief Business Officer, Da Volterra
12.4. Gregory J. Kuehn, Vice President, Business Development and Marketing, Metabiomics
12.5. Dr. Mark Heiman, Vice President of Research and Chief Scientific Officer, MicroBiome Therapeutics
12.6. Lee Jones, President and CEO, Rebiotix
13. APPENDIX 1: TABULATED DATA
14. APPENDIX 2: LIST OF COMPANIES AND ORGANISATIONS
Figure 3.1 Achievements of the Human Microbiome Project
Figure 3.2 Factors Affecting the Gut Flora
Figure 3.3 Factors Affecting the Infant Gut Microbiota
Figure 4.1 Microbiome Therapeutics: Distribution by Phase of Development
Figure 4.2 Microbiome Therapeutics: Distribution by Type of Product
Figure 4.3 Microbiome Therapeutics: Distribution by Geography
Figure 4.4 Microbiome Therapeutics: Distribution by Therapeutic Area
Figure 4.5 Microbiome Therapeutics: Distribution by Therapeutic Area and Phase of Development
Figure 4.6 Microbiome Therapeutics: Active Industry Players
Figure 5.1 Probiotic Drugs: Modes of Action
Figure 5.2 Probiotic and Prebiotic Drugs: Distribution by Number of Products
Figure 5.3 Probiotic and Prebiotic Drugs: Distribution by Phase of Development
Figure 5.4 Probiotic and Prebiotic Drugs: Distribution by Therapeutic Area
Figure 5.5 Probiotic and Prebiotic Drugs: Distribution by Geography
Figure 5.6 Probiotic and Prebiotic Drugs: Active Industry Players
Figure 6.1 Clostridium difficile Infections (CDI): Pipeline by Product Type and Development Stage
Figure 6.2 Irritable Bowel Syndrome (IBS): Pipeline by Product Type and Development Stage
Figure 6.3 Diabetes: Pipeline by Product Type and Development Stage
Figure 7.1 Number of Funding Instances by Year, 2005 Onwards
Figure 7.2 Amount Invested by Year, 2005 Onwards
Figure 7.3 Funding Instances: Distribution by Type, 2005-2015
Figure 7.4 Funding Instances: Distribution by Total Amount Invested, 2005-2015 (USD Million)
Figure 7.5 Funding Instances: Distribution by Range of Amount Invested by Type of Funding (USD Million)
Figure 7.6 Most Active Players: Distribution by Number of Funding Instances, 2005-2015
Figure 7.7 Most Active VC Firms/Investors: Distribution by Number of Instances, 2005, 2015
Figure 7.8 Funding Instances: Distribution by Type of Application
Figure 7.9 Funding Instances: Distribution by Type of Product
Figure 8.1 Recent Collaborations: Distribution by Year
Figure 8.2 Recent Collaborations: Distribution by Type of Application
Figure 8.3 Recent Collaborations: Distribution by Type of Therapeutic Product
Figure 8.4 Recent Collaborations: Distribution by Type of Model
Figure 8.5 Recent Collaborations: Distribution by Company
Figure 9.1 Microbiome Therapeutics Market Forecast (USD Million), Short Term, Base Case, 2015 - 2022
Figure 9.2 Microbiome Therapeutics Market Forecast (USD Million), Mid-Long Term, Base Case, 2022 – 2030
Figure 9.3 Microbiome Therapeutics Market: Distribution by Therapeutic Area, 2025, 2030
Figure 9.4 Microbiome Therapeutics Market: Distribution by Function, 2030
Figure 10.1 Advantages of Different Formulations of C16G2
Figure 10.2 OpenBiome: Revenues 2014, Distribution by Different Segments (USD Million)
Figure 10.3 Second Genome Solutions Program
Figure 11.1 Microbiome Therapeutics Market (USD Million), 2015, 2022, 2030
Table 3.1 Microbiota in the GI Tract
Table 4.1 Microbiome Therapeutics: Development Pipeline
Table 4.2 FMT Therapies: Development Pipeline
Table 4.3 Microbiome Diagnostics: Development Pipeline
Table 4.4 Microbiome Based Medical Food Supplements and Consumer Products for Humans: Development Pipeline
Table 5.1 Foods Containing Prebiotics
Table 5.2 Probiotic and Prebiotic Drugs: Development Pipeline
Table 6.1 Clostridium difficile Infections (CDI): Diagnostic Tests
Table 6.2 Clostridium difficile Infections (CDI) and Other Hospital Acquired Infections: Microbiome Therapeutics Pipeline
Table 6.3 Irritable Bowel Syndrome (IBS): Current Medication
Table 6.4 Irritable Bowel Syndrome (IBS): Microbiome Therapeutics Pipeline
Table 6.5 Ulcerative Colitis: Microbiome Therapeutics Pipeline
Table 6.6 Crohn’s Disease: Current Medication
Table 6.7 Crohn’s Disease: Microbiome Therapeutics Pipeline
Table 6.8 Diabetes: Current Medications
Table 6.9 Diabetes: Microbiome Therapeutics Pipeline
Table 6.10 Obesity: Microbiome Therapeutics Pipeline
Table 6.11 Bacterial Vaginosis (BV): Current Medication
Table 6.12 Bacterial Vaginosis (BV): Microbiome Therapeutics Pipeline
Table 7.1 List of Funding Instances and Investors, 2005-2015
Table 7.2 Types of Funding Instances, 2005- 2015
Table 7.3 Amount Invested by Product Type, 2005- 2015 (USD Million)
Table 8.1 Microbiome Therapies: Recent Collaborations (2005-2015)
Table 9.1 Potential Therapeutic Areas: Estimated Market Growth Rate
Table 9.2 Potential Therapeutic Areas: Estimated Penetration (By 2030)
Table 10.1 C3 Jian: Product Portfolio, Microbiome Therapeutics
Table 10.2 Different Formulations of C16G2
Table 10.3 C3 Jian: Product Portfolio, Microbiome Diagnostics
Table 10.4 Enterome Bioscience: Product Portfolio, Microbiome Therapeutics
Table 10.5 Enterome Bioscience: Product Portfolio, Microbiome Diagnostics
Table 10.6 Immuron: Product Portfolio, Microbiome Therapeutics
Table 10.7 MicroBiome Therapeutics: Product Portfolio, Microbiome Therapeutics
Table 10.8 OpenBiome: Product Portfolio, FMT
Table 10.9 FMP 30: Specifications
Table 10.10 FMP 250: Specifications
Table 10.11 Osel: Product Portfolio, Microbiome Therapeutics
Table 10.12 Rebiotix: Product Portfolio, Microbiome Therapeutics
Table 10.13 Ritter Pharmaceuticals: Product Portfolio, Microbiome Therapeutics
Table 10.14 Second Genome: Product Portfolio, Microbiome Therapeutics
Table 10.15 Seres Therapeutics: Product Portfolio, Microbiome Therapeutics
Table 10.16 Synthetic Biologics: Product Portfolio, Microbiome Therapeutics
Table 13.1 Microbiome Therapies: Distribution by Phase of Development
Table 13.2 Microbiome Therapies: Distribution by Type of Product
Table 13.3 Microbiome Therapies: Distribution by Geography
Table 13.4 Microbiome Therapies: Distribution by Therapeutic Area
Table 13.5 Microbiome Therapeutics: Distribution by Therapeutic Area and Phase of Development
Table 13.6 Microbiome Therapeutics: Active Industry Players
Table 13.7 Probiotic and Prebiotic Drugs: Distribution by Numbers of Products
Table 13.8 Probiotic and Prebiotic Drugs: Distribution by Phase of Development
Table 13.9 Probiotic and Prebiotic Drugs: Active Industry Players
Table 13.10 Probiotic and Prebiotic Drugs: Distribution by Geography
Table 13.11 Probiotic and Prebiotic Drugs: Active Industry Players
Table 13.12 Clostridium difficile Infections (CDI): Pipeline by Product Type and Development Stage
Table 13.13 Irritable Bowel Syndrome (IBS): Pipeline by Product Type and Development Stage
Table 13.14 Diabetes: Pipeline by Product Type and Development Stage
Table 13.15 Number of Funding Instances by Year, 2005 Onwards
Table 13.16 Amount Invested by Year, 2005 Onwards
Table 13.17 Funding Instances: Distribution by Type, 2005-2015
Table 13.18 Funding Instances: Distribution by Total Amount Invested, 2005-2015 (USD Million)
Table 13.19 Most Active Players: Distribution by Number of Funding Instances, 2005-2015
Table 13.20 Most Active VC Firms/Investors: Distribution by Number of Instances, 2005-2015
Table 13.21 Funding Instances: Distribution by Type of Application
Table 13.22 Funding Instances: Distribution by Type of Product
Table 13.23 Recent Collaborations: Distribution by Year
Table 13.24 Recent Collaborations: Distribution by Type of Application
Table 13.25 Recent Collaborations: Distribution by Type of Therapeutic Product
Table 13.26 Recent Collaborations: Distribution by Type of Model
Table 13.27 Recent Collaborations: Distribution by Company
Table 13.28 Microbiome Therapeutics Market Forecast (USD Million), Short Term, Base Case, 2015-2022
Table 13.29 Microbiome Therapeutics Market Forecast (USD Million), Short Term, Conservative Case, 2015-2022
Table 13.30 Microbiome Therapeutics Market Forecast (USD Million), Short Term, Optimistic Case, 2015-2022
Table 13.31 Microbiome Therapeutics Market Forecast (USD Million), Mid-Long Term, Base Case, 2022-2030
Table 13.32 Microbiome Therapeutics Market Forecast (USD Million), Mid-Long Term, Conservative Case, 2022-2030
Table 13.33 Microbiome Therapeutics Market Forecast (USD Million), Mid-Long Term, Optimistic Case, 2022-2030
Table 13.34 Microbiome Therapeutics Market: Distribution by Therapeutic Area, 2025, 2030
Table 13.35 Microbiome Therapeutics Market: Distribution by Function, 2030
Table 13.36 OpenBiome: Revenues 2014, Distribution by Different Segments (USD Million)
Table 13.37 Microbiome Therapeutics Market (USD million), 2015, 2022, 2030
The following companies and institutes have been mentioned in this report.
PRICING DETAILS
Discounts available for multiple report purchases
sales@rootsanalysis.com
SUBSCRIBE TO INDUSTRY UPDATES